Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulforafan alfadex - TheraCryf

Next Previous
Drug Profile

Sulforafan alfadex - TheraCryf

Alternative Names: Broccoli-sprout-extract; SFX-01; Stabilised sulforaphane; STP-2; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadex

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lalilab
  • Developer Lalilab; TheraCryf
  • Class Antihaemorrhagics; Antineoplastics; Behavioural disorder therapies; Chemopreventatives; Phytotherapies
  • Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF-E2-related factor 2 stimulants; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III SARS-CoV-2 acute respiratory disease
  • Phase II Breast cancer; Subarachnoid haemorrhage
  • Phase I Glioblastoma; Pervasive child development disorders
  • Preclinical Adenocarcinoma; Haematological malignancies; Rhabdomyosarcoma
  • No development reported Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia; Multiple sclerosis

Most Recent Events

  • 25 Apr 2025 Preclinical trials in Adenocarcinoma in USA (PO), prior to April 2025
  • 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Adenocarcinoma presented at the 116th Annual Meeting of the American Association for Cancer Research 2025 (AACR-2025)
  • 29 Jul 2024 Phase-I clinical trials in Glioblastoma (unspecified route) before July 2024 (Evgen pipeline, July 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top